Kymera Therapeutics (KYMR) risk factors
Item 1A of every Kymera Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors83 risks3 new2 dropped14 reworded
Kymera added risks around operational restructuring, third-party collaborations, and IP litigation. Tax disclosures now explicitly cite the OBBBA enacted July 4, 2025. Macro risks incorporate new tariffs and policy changes under the 2025 administration.
Filed Feb 26, 2026 - FY2024 10-K risk factors82 risks
Kymera faces intense risks from its unproven targeted protein degradation platform and heavy reliance on early-stage pipeline success. The company requires ongoing capital raises and depends on limited third-party suppliers for drug materials. Extensive regulation, pricing controls, and clinical trial execution heavily impact future viability.
Filed Feb 27, 2025